Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Linezolid

Linezolid Sale

(Synonyms: 利奈唑胺; PNU-100766) 目录号 : GC11221

An antibiotic active against Gram-positive bacteria

Linezolid Chemical Structure

Cas No.:165800-03-3

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥424.00
现货
10mg
¥385.00
现货
25mg
¥700.00
现货
50mg
¥1,260.00
现货
100mg
¥2,100.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Antibacterial test [1]:

Bacteria

E. coli UC6782

Preparation method

The solubility of this compound in DMSO is > 16.9 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

0.01 ~ 1000 μM; 60 mins

Applications

Linezolid potently inhibited protein synthesis in E. coli UC6782, with the IC90 value of 30 μM. Linezolid was at least 2.5 times more potent than DuP-721 and about twice as potent as streptomycin.

References:

[1]. Shinabarger D L, Marotti K R, Murray R W, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions[J]. Antimicrobial agents and chemotherapy, 1997, 41(10): 2132-2136.

产品描述

Linezolid, a synthetic oxazolidinone antimicrobial, shows a wide spectrum against Gram-positive bacteria andmultidrug-resistant bacteria such as anaerobes, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, penicillin-resistant pneumococci and streptococcus [1,2].

Oxazolidinones could inhibit protein synthesis by binding to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevent the formation of a functional 70S-initiation complex. Linezolid is also a weak, nonselective and reversible inhibitor of monoamine oxidase [2].

In Vitro: Linezolid was a potent inhibitor of cell-free transcription-translation in E. coli. IC50 was 1.8 mM[3]. linezolid MICs vary slightly owing to the different test method and laboratory. The MIC values were between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci [4].

Clinical Trials: Linezolid is fully bioavailable following oral administration, with maximum plasma linezolid concentrations achieved between 1 and 2 hours after oral administration. The elimination half-life of linezolid is 5–7 hours, and twice-daily administration of 400–600mg provides steady-state concentrations in the therapeutic range[5].

In clinical trials involving hospitalised patients with skin/soft tissue infections (predominantly S. aureus), intravenous/oral administration of linezolid (up to 1250 mg/day) produced clinical success in > 83% of individuals. In patients with community-acquired pneumonia, success rates were > 94%[6]. Linezolid could also be used in patients with nosocomial pneumonia[7].Linezolid appears to be well tolerated and the most common side effects is gastrointestinal disturbances [6].

References:
[1] Tsiodras S, Gold H S, Sakoulas G, et al.  Linezolid resistance in a clinical isolate of Staphylococcus aureus[J]. The Lancet, 2001, 358(9277): 207-208.
[2] Swaney S M, Aoki H, Ganoza M C, et al.  The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria[J]. Antimicrobial agents and chemotherapy, 1998, 42(12): 3251-3255.
[3] Shinabarger D L, Marotti K R, Murray R W, et al.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions[J]. Antimicrobial agents and chemotherapy, 1997, 41(10): 2132-2136.
[4] Livermore D M.  Linezolid in vitro: mechanism and antibacterial spectrum[J]. Journal of antimicrobial chemotherapy, 2003, 51(suppl 2): ii9-ii16.
[5] Stalker D J, Jungbluth G L.  Clinical pharmacokinetics of linezolid, a novel oxazolidinoneantibacterial[J]. Clinical pharmacokinetics, 2003, 42(13): 1129-1140.
[6] Clemett D, Markham A.  Linezolid[J]. Drugs, 2000, 59(4): 815-827.
[7] Wunderink R G, Cammarata S K, Oliphant T H, et al.  Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia[J]. Clinical therapeutics, 2003, 25(3): 980-992.

Chemical Properties

Cas No. 165800-03-3 SDF
别名 利奈唑胺; PNU-100766
化学名 N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
Canonical SMILES CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F
分子式 C16H20FN3O4 分子量 337.35
溶解度 ≥ 16.85mg/mL in DMSO, ≥ 9.5 mg/mL in EtOH with ultrasonic, ≥ 2.48 mg/mL in Water with ultrasonic and warming 储存条件 4°C, protect from light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.9643 mL 14.8214 mL 29.6428 mL
5 mM 0.5929 mL 2.9643 mL 5.9286 mL
10 mM 0.2964 mL 1.4821 mL 2.9643 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置